Welcome to our dedicated page for Clearpoint Neuro news (Ticker: CLPT), a resource for investors and traders seeking the latest updates and insights on Clearpoint Neuro stock.
ClearPoint Neuro Inc. (NASDAQ: CLPT) is a leader in MRI-guided neurosurgical navigation systems and targeted therapeutic delivery solutions for neurological disorders. This page serves as the definitive source for official company announcements, regulatory updates, and strategic developments in precision neurosurgery and cell/gene therapy delivery.
Access real-time updates on CLPT's innovative medical devices, including the SmartFlow® Cannula and Prism® Laser Therapy System. Stay informed about FDA clearances, biopharma partnerships, clinical trial milestones, and financial disclosures that demonstrate the company's progress in advancing minimally invasive neurological treatments.
Key updates include earnings reports, product launch announcements, research collaborations with academic institutions, and expansion of global clinical sites. Our curated news collection enables investors and healthcare professionals to track CLPT's role in enabling next-generation therapies for Parkinson's disease, brain tumors, and rare genetic conditions.
Bookmark this page for streamlined access to ClearPoint Neuro's latest achievements in neurosurgical navigation technology and therapeutic delivery systems. Check regularly for verified updates on regulatory approvals, intellectual property developments, and strategic initiatives shaping the future of precision neurology.
ClearPoint Neuro, Inc. (Nasdaq: CLPT) will present novel research and exhibit at the 27th American Society of Gene & Cell Therapy Annual Meeting. The Company offers navigation to the brain and spine, showcasing abstracts and technology collaborations. The ASGCT Annual Meeting serves as a platform for networking and attracting new customers. ClearPoint Neuro provides clinical products and pre-clinical development services for controlled drug and device delivery, with a global presence in healthcare and research centers.
ClearPoint Neuro, Inc. announced FDA clearance for its Prism Bone Anchor Accessory, supporting the ClearPoint Prism Neuro Laser Therapy System, expanding into the operating room. The accessory will enable precise navigation for laser therapy in the brain and spine, with a market release in Q2 2024 and full market release in the second half of the year.
FAQ
What is the current stock price of Clearpoint Neuro (CLPT)?
What is the market cap of Clearpoint Neuro (CLPT)?
